Showing 1031-1040 of 1321 results for "".
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- Allergan's CoolSculpting Treatment Now FDA Approved to Improve Appearance Of Lax Tissue in Double Chinhttps://practicaldermatology.com/news/allergans-coolsculpting-treatment-now-fda-approved-to-improve-appearance-of-lax-tissue-in-double-chin/2457956/The FDA has approved Allergan plc's CoolSculpting treatment for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one tr
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- FDA Approves Injection of Restylane Silk via Cannula for Lip Augmentationhttps://practicaldermatology.com/news/fda-approves-injection-of-restylane-silk-via-cannula-for-lip-augmentation/2458012/The FDA has approved the use of a small blunt tip cannula with Galderma's Restylane Silk for lip augmentation. Restylane Silk was the first FDA-approved hyaluronic acid (HA) dermal filler specifically designed for lip augmentation and the smoothing of wrinkles around the mouth in patients 21
- Meet Thermage's New FLX Systemhttps://practicaldermatology.com/news/meet-thermages-new-flxtm-system/2458026/The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a new optimized energy delivery algorithm, know
- ISHRS: Hair Restoration Surgery at All-Time Highhttps://practicaldermatology.com/news/ishrs-hair-restoration-surgery-at-all-time-high/2458029/Hair restoration is having a moment. The worldwide volume of surgical hair restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures performed worldwide in 2016, according to the latest’s statistics from the
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial tre
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://practicaldermatology.com/news/fda-clears-fontinas-starwalker-maqx-ultra-performance-q-switched-system/2458038/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T